DE60010127D1 - Verfahren zur ermittlung der empfindlichkeit von hiv-varianten gegen hemmstoffe der hiv-protease - Google Patents

Verfahren zur ermittlung der empfindlichkeit von hiv-varianten gegen hemmstoffe der hiv-protease

Info

Publication number
DE60010127D1
DE60010127D1 DE60010127T DE60010127T DE60010127D1 DE 60010127 D1 DE60010127 D1 DE 60010127D1 DE 60010127 T DE60010127 T DE 60010127T DE 60010127 T DE60010127 T DE 60010127T DE 60010127 D1 DE60010127 D1 DE 60010127D1
Authority
DE
Germany
Prior art keywords
hiv
coding sequence
protease
hiv protease
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60010127T
Other languages
English (en)
Inventor
Stefano Menzo
Massimo Clementi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biostrands SRL
Original Assignee
Biostrands SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biostrands SRL filed Critical Biostrands SRL
Application granted granted Critical
Publication of DE60010127D1 publication Critical patent/DE60010127D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/161—HIV-1, HIV-2 gag-pol, e.g. p55, p24/25, p17/18, p.7, p6, p66/68, p51/52, p31/34, p32, p40

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
DE60010127T 1999-12-15 2000-12-14 Verfahren zur ermittlung der empfindlichkeit von hiv-varianten gegen hemmstoffe der hiv-protease Expired - Lifetime DE60010127D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99830776A EP1109019A1 (de) 1999-12-15 1999-12-15 Verfahren zur Ermittlung der Empfindlichkeit von HIV-Varianten gegen Hemmstoffe der HIV-Protease
PCT/IT2000/000518 WO2001044508A2 (en) 1999-12-15 2000-12-14 Method to evaluate the sensitivity of hiv variants to drugs able to inhibit the hiv protease

Publications (1)

Publication Number Publication Date
DE60010127D1 true DE60010127D1 (de) 2004-05-27

Family

ID=8243712

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60010127T Expired - Lifetime DE60010127D1 (de) 1999-12-15 2000-12-14 Verfahren zur ermittlung der empfindlichkeit von hiv-varianten gegen hemmstoffe der hiv-protease

Country Status (9)

Country Link
US (1) US20030175690A1 (de)
EP (2) EP1109019A1 (de)
AT (1) ATE265043T1 (de)
AU (1) AU2395101A (de)
BR (1) BR0016409A (de)
CA (1) CA2393620A1 (de)
DE (1) DE60010127D1 (de)
RU (1) RU2002118706A (de)
WO (1) WO2001044508A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0009374D0 (en) * 2000-04-14 2000-05-31 Glaxo Group Ltd Phenotyping assay and reagents therefor
AU2003246119B2 (en) * 2002-06-28 2008-02-21 Fuso Pharmaceutical Industries, Ltd. Anti-HIV agent

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571666A (en) * 1988-10-28 1996-11-05 Oklahoma Medical Research Foundation Thiazine dyes used to inactivate HIV in biological fluids
ES2177922T3 (es) * 1996-01-26 2002-12-16 Virco Bvba Metodo de valoracion la quimioterapia de pacientes hiv-positivos basado en la sensibilidad fenotipica a los farmacos de las cepas de hiv delpaciente.

Also Published As

Publication number Publication date
WO2001044508A3 (en) 2002-01-03
RU2002118706A (ru) 2004-02-27
BR0016409A (pt) 2002-08-20
EP1242818B1 (de) 2004-04-21
EP1242818A2 (de) 2002-09-25
ATE265043T1 (de) 2004-05-15
AU2395101A (en) 2001-06-25
CA2393620A1 (en) 2001-06-21
US20030175690A1 (en) 2003-09-18
EP1109019A1 (de) 2001-06-20
WO2001044508A2 (en) 2001-06-21

Similar Documents

Publication Publication Date Title
FR2808803B1 (fr) Cellules es modifiees et gene specifique de cellules es
ATE421999T1 (de) Nachweis von hiv-1 durch amplifizierung von nukleinsäuren
ATE318896T1 (de) Rekombinante rna-replikase von hepatitis-c-virus
Geis et al. Unintegrated HIV-1 DNAs are loaded with core and linker histones and transcriptionally silenced
EA200400329A1 (ru) Способы амплификации нуклеиновых кислот
Semaan et al. Cytotoxic effects during knock out of multiple porcine endogenous retrovirus (PERV) sequences in the pig genome by zinc finger nucleases (ZFN)
DE69840743D1 (de) Nukleinsäure-primer und -sonden zur detektion von hiv-1 und hiv-2
DE50214416D1 (de) Vermehrung von viren in zellkultur
CN113564149B (zh) 一种三联体融合蛋白及其在病毒自剪切蛋白酶抑制剂活性评估和筛选时的应用
ATE318930T1 (de) Nukleinsäuresonden zur detektion von candida- spezies
Lin et al. Study on factors affecting the performance of a CRISPR/Cas-Assisted new immunoassay: detection of salivary insulin as an example
DE60010127D1 (de) Verfahren zur ermittlung der empfindlichkeit von hiv-varianten gegen hemmstoffe der hiv-protease
DE60129809D1 (de) In vitro evolution von nukleinsäuren und kodierten polypeptiden
ES2054769T3 (es) Polipeptidos hiv-2 recombinantes.
Bona et al. Development of a human immunodeficiency virus vector-based, single-cycle assay for evaluation of anti-integrase compounds
ATE386140T1 (de) Methoden und reagenzien zur in situ amplifizierung
ATE333519T1 (de) Electrochemisches verfahren zum nachweis von nukleinsäuren
Khan et al. Contesting the evidence for− 1 frameshifting in immune-functioning CC chemokine receptor 5 (CCR5)–the HIV-1 co-receptor
Müller et al. Cell biological aspects of HIV-1 infection: effect of the anti-HIV-1 agent avarol
EA199800438A1 (ru) Способ и набор для количественного определения и обнаружения микроорганизмов
DE60045932D1 (de) HIV-1-Sequenzverstärkung zur Erkennung von Sequenzen in Zusammenhang mit Wirkstoffresistenz-Mutationen
WO2001079853A3 (de) TESTSYSTEM ZUR CHARAKTERISIERUNG VON MODULATOREN DES SPLEISSPROZESSES VON mRNA IN LEBENDEN ZELLEN (IN VIVO), DESSEN HERSTELLUNG UND VERWENDUNG
ATE269417T1 (de) Verfahren zur erkennung und messung von gespleisten nukleinsäuren
ATE403863T1 (de) Verfahren zum nachweis von intrazellulären atp und/oder genexpression
Cao et al. Label-Free and DNAzyme-Mediated Biosensor with a High Signal-to-Noise Ratio for a Lumpy Skin Disease Virus Assay

Legal Events

Date Code Title Description
8332 No legal effect for de